Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Management of CAR-T cell-related encephalopathy syndrome in adult and pediatric patients: Recommendations of the French Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC)].
Cornillon J, Hadhoum N, Roth-Guepin G, Quessar A, Platon L, Ouachée-Chardin M, Nicolas-Virelizier E, Naudin J, Moreau AS, Masouridi-Levrat S, Borel C, Ahmad I, Beauvais D, Baruchel A, Yakoub-Agha I. Cornillon J, et al. Bull Cancer. 2020 Jan;107(1S):S12-S17. doi: 10.1016/j.bulcan.2019.05.001. Epub 2019 Jun 13. Bull Cancer. 2020. PMID: 31202556 French.
Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.
Perrot A, Monjanel H, Bouabdallah R, Quittet P, Sarkozy C, Bernard M, Stamatoullas A, Borel C, Bouabdallah K, Nicolas-Virelizier E, Fournier M, Morschhauser F, Brice P; Lymphoma Study Association (LYSA). Perrot A, et al. Haematologica. 2016 Apr;101(4):466-73. doi: 10.3324/haematol.2015.134213. Epub 2016 Jan 14. Haematologica. 2016. PMID: 26768687 Free PMC article.
[Management of cytokine release syndrome in adult and pediatric patients undergoing CAR-T cell therapy for hematological malignancies: Recommendation of the French Society of Bone Marrow and cellular Therapy (SFGM-TC)].
Yakoub-Agha I, Moreau AS, Ahmad I, Borel C, Hadhoum N, Masouridi-Levrat S, Naudin J, Nicolas-Virelizier E, Ouachée-Chardin M, Platon L, Quessar A, Roth-Guepin G, Beauvais D, Baruchel A, Cornillon J. Yakoub-Agha I, et al. Bull Cancer. 2019 Jan;106(1S):S102-S109. doi: 10.1016/j.bulcan.2018.12.001. Epub 2019 Jan 17. Bull Cancer. 2019. PMID: 30661749 Review. French.
BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Cornillon J, Daguenet E, Bay JO, Chauchet A, Salles G, Contentin N, Nicolas-Virelizier E, Mercier M, Vallet N, Alexis M, Chrétien ML, Cluzeau T, Huynh A, Himberlin C, Dorvaux V, Amorim S, Lejeune C, de Latour RP, Gyan E. Cornillon J, et al. Ann Hematol. 2019 Aug;98(8):1973-1980. doi: 10.1007/s00277-019-03704-z. Epub 2019 May 20. Ann Hematol. 2019. PMID: 31111177
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.
Manson G, Mear JB, Herbaux C, Schiano JM, Casasnovas O, Stamatoullas A, Deau B, Schmitt A, Garnier G, Regny C, Bouabdallah K, Moles-Moreau MP, Ghesquieres H, Tempescul A, Dulery R, Nicolas-Virelizier E, Delmer A, Borel C, Chauchet A, Damotte D, Dercle L, Brice P, Houot R; LYSA. Manson G, et al. Eur J Cancer. 2019 Jul;115:47-56. doi: 10.1016/j.ejca.2019.04.006. Epub 2019 May 10. Eur J Cancer. 2019. PMID: 31082693
Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma.
Mokrane FZ, Chen A, Schwartz LH, Morschhauser F, Stamatoullas A, Schiano de Colella JM, Vercellino L, Casasnovas O, Chauchet A, Delmer A, Nicolas-Virelizier E, Ghesquières H, Moles-Moreau MP, Schmitt A, Duléry R, Bouabdallah K, Borel C, Touati M, Deau-Fischer B, Peyrade F, Seban RD, Manson G, Houot R, Dercle L. Mokrane FZ, et al. Radiology. 2020 Jun;295(3):651-661. doi: 10.1148/radiol.2020192056. Epub 2020 Apr 14. Radiology. 2020. PMID: 32286191
Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA).
Manson G, Herbaux C, Schiano JM, Casasnovas O, Stamatoullas A, Deau B, Schmitt A, Regny C, Bouabdallah K, Chauchet A, Ghesquieres H, Tempescul A, Dulery R, Nicolas-Virelizier E, Delmer A, Borel C, Dercle L, Brice P, Houot R; Lymphoma Study Association (LYSA). Manson G, et al. Br J Haematol. 2022 Jul;198(1):203-206. doi: 10.1111/bjh.18198. Epub 2022 Apr 21. Br J Haematol. 2022. PMID: 35445392 Free article. No abstract available.
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
Stamatoullas A, Ghesquières H, Feugier P, André M, Le Bras F, Gac AC, Borel C, Gastinne T, Quittet P, Morschhauser F, Ribrag V, Guidez S, Nicolas-Virelizier E, Berriolo-Riedinger A, Vander Borght T, Edeline V, Brice P. Stamatoullas A, et al. Among authors: nicolas virelizier e. Leuk Lymphoma. 2022 Dec;63(13):3063-3071. doi: 10.1080/10428194.2022.2107204. Epub 2022 Aug 17. Leuk Lymphoma. 2022. PMID: 35975738 Clinical Trial.
Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.
Sellner L, Boumendil A, Finel H, Choquet S, de Rosa G, Falzetti F, Scime R, Kobbe G, Ferrara F, Delmer A, Sayer H, Amorim S, Bouabdallah R, Finke J, Salles G, Yakoub-Agha I, Faber E, Nicolas-Virelizier E, Facchini L, Vallisa D, Zuffa E, Sureda A, Dreger P; EBMT Lymphoma Working Party. Sellner L, et al. Bone Marrow Transplant. 2016 Feb;51(2):212-218. doi: 10.1038/bmt.2015.273. Epub 2015 Nov 16. Bone Marrow Transplant. 2016. PMID: 26569093
69 results